Novocure Ltd Stock
Your prediction
Novocure Ltd Stock
We can see a decrease in the price for Novocure Ltd. Compared to yesterday it has lost -€0.135 (-1.160%).
Our community identified positive and negative aspects for Novocure Ltd stock for the coming years. 1 users see the criterium "Shareholder structure" as a plus for the Novocure Ltd stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Novocure Ltd in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Novocure Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -14.490% | -75.357% | -72.809% | -71.362% | -95.447% |
| Alnylam Pharmace. | -4.550% | -13.930% | -13.424% | 40.381% | 49.889% | 54.154% | 216.094% |
News
Novocure: Steady Ahead of Key Milestones
Here's our initial take on Novocure's (NASDAQ: NVCR) fiscal 2025 second-quarter financial report.
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable
Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and